Neoprobe, Cardinal Health ink terms for Lymphoseek distribution:
This article was originally published in Clinica
Manufacturer of oncology and cardiovascular products Neoprobe has signed a non-binding term sheet with Cardinal Health for the exclusive US marketing and distribution rights to its Lymphoseek radioactive lymphatic mapping targeting agent. Cardinal Health, headquartered in Dublin, Ohio, will provide Neoprobe with a distribution network of more than 150 nuclear pharmacies, and its wholesale distribution operations to in-hospital nuclear pharmacies. Neoprobe, also located in Dublin, Ohio, is developing Lymphoseek for use with hand-held gamma detection devices, and is preparing to submit a phase III multicenter clinical trial to the FDA.